The contract manufacturing market for Pharmaceuticals in China is projected ..

Roots Analysis has done a detailed study on China Pharmaceutical Contract Manufacturing Services Market, 2020-2030, covering key aspects of the industry and identifying key future growth opportunities.
To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link
Key Market Insights 
  • Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing
  • CMOs have established manufacturing facilities across different regions of China; Eastern China has emerged as a popular hub, serving as a base of operations for many contract service providers
  • The current, installed manufacturing capacity of pharmaceutical CMOs in China is estimated to be over 46 million liters; interestingly, capacity utilization has been observed to be ~75% over the last few years
  • Big pharma players have also invested significantly in this region for initiatives related to the establishment or expansion of R&D centers and manufacturing facilities focused on pharmaceutical products
  • Innovator companies are expected to continue outsourcing clinical and commercial manufacturing operations to China-based CMOs; the contract services industry in the region is likely to grow at a CAGR of ~8.9%
  • In the long-term, the projected future opportunity is anticipated to be well distributed across various market segments, such as different types of products (APIs and FDFs), region (eastern china, southern china, western china) and others

For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
 
Table of Contents
 
1.                     PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2.                     EXECUTIVE SUMMARY

3.                     INTRODUCTION
3.1. Chapter Overview
3.2. Need for Outsourcing in the Pharmaceutical Industry
3.3. Overview of the Pharmaceutical Contract Manufacturing
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1.                Traditional Contract Manufacturing Organizations (CMOs)
3.4.2.                Modern CMOs
3.5. Services Offered by CMOs
3.6.                  Pharmaceutical Contract Manufacturing Scenario in China
3.7.                  Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs
 
4.                     CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies


4.2.1.                Comparison of General Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3.                Comparison of Key Manufacturing-related Challenges
 
5.                     MARKET OVERVIEW
5.1. Chapter Overview
5.2.                   Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1.                Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3.                Analysis by Location of Headquarters
5.2.4.                Analysis by Type of Product (API and FDF)
5.2.5. Analysis by Type of FDF
5.2.6.                Analysis by Type of Packaging
5.2.7.                Analysis by Manufacturing Facilities
5.3.                   Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1.                Analysis by Year of Establishment
5.3.2.                Analysis by Company Size
5.3.3.                Analysis by Location of Headquarters
5.3.4.                Analysis by Type of Product (API and FDF)
5.3.5.                Analysis by Type of FDF
5.3.6.                Analysis by Type of Packaging
5.3.7                 Analysis by Manufacturing Facilities
 
6.                     MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Chinese Pharmaceutical CMOs: List of Manufacturing Facilities

6.2.1. Analysis by CMO Manufacturing Facilities in Eastern China
6.2.2. Analysis by CMO Manufacturing Facilities in Southern China
6.2.3. Analysis by CMO Manufacturing Facilities in Northern China


7.                     PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA 
7.1.                   Chapter Overview
7.1.1.                Health Authorities in China
7.1.2.                Overview of Regulatory Guidelines in China
 
8.                     COMPANY PROFILES
8.1.                   Chapter Overview
8.2.                   2Y-Chem
8.2.1.                Company Overview
8.2.2.                Service Portfolio
8.2.3.                China-based Manufacturing Facilities and Capabilities
8.2.4.                Recent Developments and Future Outlook
 
8.3.                   Aurisco Pharmaceutical
8.3.1.                Company Overview
8.3.2.                Service Portfolio
8.3.3.                China-based Manufacturing Facilities and Capabilities
8.3.4.                Recent Developments and Future Outlook
 
8.4.                   ChemPartner
8.4.1.                Company Overview
8.4.2.                Service Portfolio
8.4.3.                China-based Manufacturing Facilities and Capabilities
8.4.4.                Recent Developments and Future Outlook
 
8.5.                   Dorrapharma
8.5.1.                Company Overview
8.5.2.                Service Portfolio
8.5.3.                China-based Manufacturing Facilities and Capabilities
8.5.4.                Recent Developments and Future Outlook
 
8.6.                   Hubei Biocause Pharmaceutical
8.6.1.                Company Overview
8.6.2.                Service Portfolio
8.6.3.                China-based Manufacturing Facilities and Capabilities
8.6.4.                Recent Developments and Future Outlook
 
8.7.                   Infoark
8.7.1.                Company Overview
8.7.2.                Service Portfolio
8.7.3.                China-based Manufacturing Facilities and Capabilities
8.7.4.                Recent Developments and Future Outlook
 
8.8.                   Ningbo Menovo Pharmaceutical
8.8.1.                Company Overview
8.8.2.                Service Portfolio
8.8.3.                China-based Manufacturing Facilities and Capabilities
8.8.4.                Recent Developments and Future Outlook
 
8.9.                   Shandong Xinhua Pharmaceutical
8.9.1.                Company Overview
8.9.2.                Service Portfolio
8.9.3.                China-based Manufacturing Facilities and Capabilities
8.9.4.                Recent Developments and Future Outlook
 
8.10.                 Shanghai Acebright Pharmaceuticals
8.10.1.             Company Overview
8.10.2.             Service Portfolio
8.10.3.             China-based Manufacturing Facilities and Capabilities
8.10.4.             Recent Developments and Future Outlook
           
8.11.                 STA Pharmaceutical
8.11.1.             Company Overview
8.11.2.             Service Portfolio
8.11.3.             China-based Manufacturing Facilities and Capabilities
8.11.4.             Recent Developments and Future Outlook
 
8.12.                 Zhejiang Huahai Pharmaceutical
8.12.1.             Company Overview
8.12.2.             Service Portfolio
8.12.3.             China-based Manufacturing Facilities and Capabilities
8.12.4.             Recent Developments and Future Outlook
 
9.                     BIG PHARMA INITIATIVES IN CHINA 
9.1.                   Chapter Overview
9.2.                   Big Pharma Players: List of Initiatives
9.2.1.                Analysis by Number of Initiatives
9.2.2.                Analysis by Year of Initiative
9.2.3.                Analysis by Company and Year of Initiative
9.2.4.                Analysis by Type of Initiative
 
9.3.                   Benchmark Analysis of Big Pharma Players
9.3.1.                Harvey Ball Analysis: Summary of Investments Made
9.3.2.                Geographical Analysis by Investments Made (Facility Specific)
 
10.                    RECENT TRENDS
10.1.                 Chapter Overview
10.2.                 CMOs with Manufacturing Facilities in China: List of Partnerships
10.3.                 Analysis by Year and Type of Partnership
10.4.                 Logo Landscape of Key Partners
10.5.                 Geographical Analysis
           
11.                    CAPACITY ANALYSIS
11.1.                 Chapter Overview
11.2.                 Key Assumptions and Methodology
11.3.                 CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1.              Analysis by Company Size
11.3.2.             Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1.           Capacity Analysis: Eastern China
11.3.2.2.           Capacity Analysis: Southcentral China
11.3.2.3.           Capacity Analysis: Northern China
 
12.                    SWOT ANALYSIS
12.1.                 Chapter Overview
12.2.                 Comparison of SWOT Factors
12.3.                 Concluding Remarks
 
13.                    MARKET FORECAST
13.1.                 Chapter Overview
13.2.                 Forecast Methodology and Key Assumptions
13.3.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.4.1.              Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2.              Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3.              Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1.              API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1.           API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.1.1.1.         API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2.         API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3.         API Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2.              Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.2.1.1.         Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2.         Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3.         Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030
           
13.5.2.2.           Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3.         Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4.         Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products
13.6.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1.              Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2.              Commercial Scale Contract Manufacturing Services Market in China, 2020-2030  
13.7.                 Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3.              Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies
 
 
14.                    CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
14.1.                 Chapter Overview
14.2.                 Current Opinions and Recuperative Initiatives of Key Players
14.2.1.              Wuxi AppTec
14.2.2.              Porton Pharma Solutions
14.2.3.              Lonza
14.3.                 Impact on Future Market Opportunity for Pharmaceutical CMOs in China
15.                    CONCLUSION
 
16.                    APPENDIX 1: TABULATED DATA
 
17.                    APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
 [email protected]

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
929 Posts

Made with by Mamby